|
Laxman Pai, Opalesque Asia: European life sciences venture capital firm Sofinnova Partners has announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million ($540m). This now comprises the largest crossover investor dedicated late-stage biopharma and Medtech fund in Europe.
Paris, London, and Milan-based firm said that the fund was "oversubscribed and significantly exceeded its target," and with this latest cash boost, it's set to continue its focus on European clinical-stage companies "needing scale-up capital" while also supporting "best-in-class companies" in the U.S. and elsewhere.
To date, the fund has invested in 10 companies, each developing product meeting industry needs. Sofinnova reports that the majority of these investments from reached positive clinical trial milestones, with two investments launching NASDAQ IPOs.
"European biopharma and MedTech companies have matured tremendously in the last decade. Sofinnova Partners was the first European VC to seize the opportunity to unlock the potential of these high-growth start-ups by providing late-stage capital, building on our decades of experience funding innovative life science companies," said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners.
"With over €2 billion of assets under management dedicated to life science investing and an outstanding international team, Sofinnova Partners continues its expansion to partner with ambitious entrepr...................... To view our full article Click here
|
RSS
